Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00789854
Registration number
NCT00789854
Ethics application status
Date submitted
11/11/2008
Date registered
13/11/2008
Date last updated
23/05/2012
Titles & IDs
Public title
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
Query!
Scientific title
A Randomised, 6-week, Multicentre, Open-label, Rater-blinded Parallel Group Study Comparing Quetiapine Extended Release Monotherapy and Augmentation With Lithium Augmentation in Patients With Treatment Resistant Depression
Query!
Secondary ID [1]
0
0
D1443L00044
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RUBY
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Major Depressive Disorder
0
0
Query!
Treatment Resistant Depression
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Quetiapine XR
Treatment: Drugs - Lithium carbonate
Treatment: Drugs - SSRI/Venlafaxine
Active comparator: Add-on Quetiapine XR+SSRI/Venlafaxine - Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od).
From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline.
Active comparator: Add-on Lithium+SSRI/Venlafaxine - Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od).
From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline.
Active comparator: Monotherapy Quetiapine XR - Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)
Treatment: Drugs: Quetiapine XR
300 mg once daily (od)
Treatment: Drugs: Lithium carbonate
900 mg once daily (od)
Treatment: Drugs: SSRI/Venlafaxine
SSRI - doses within label, Venlafaxine dose up to 225 mg/day
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)
Query!
Assessment method [1]
0
0
Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.
Query!
Timepoint [1]
0
0
6 weeks treatment
Query!
Primary outcome [2]
0
0
Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)
Query!
Assessment method [2]
0
0
Change in LS mean total Montgomery Asberg Depression Rating Scale (MADRS) score from randomisation to end-of-treatment (week 6) (Scale 0-60), lower score indicates a better health status.
Query!
Timepoint [2]
0
0
6 weeks of treatment
Query!
Secondary outcome [1]
0
0
Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS =10, All Patients
Query!
Assessment method [1]
0
0
Number of patients in remission, with total Montgomery Asberg Depression Rating Scale (MADRS) score =10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
Query!
Timepoint [1]
0
0
6 weeks of treatment
Query!
Secondary outcome [2]
0
0
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) =10, Patients With One Previous Treatment Failure
Query!
Assessment method [2]
0
0
Number of patients in remission with one previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score =10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
Query!
Timepoint [2]
0
0
6 weeks of treatment
Query!
Secondary outcome [3]
0
0
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) =10, Patients With Two Previous Treatment Failure
Query!
Assessment method [3]
0
0
Number of patients in remission with two previous treatment failure and with total Montgomery Asberg Depression Rating Scale (MADRS) score =10. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
Query!
Timepoint [3]
0
0
6 weeks of treatment
Query!
Secondary outcome [4]
0
0
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) =8
Query!
Assessment method [4]
0
0
Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score =8. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
Query!
Timepoint [4]
0
0
6 weeks of treatment
Query!
Secondary outcome [5]
0
0
Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) =12
Query!
Assessment method [5]
0
0
Number of patients in remission with total Montgomery Asberg Depression Rating Scale (MADRS) score =12. MADRS scale has range from 0 to 60, where the lower score indicates the better health status.
Query!
Timepoint [5]
0
0
6 weeks of treatment
Query!
Secondary outcome [6]
0
0
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced = 50%, All Patients
Query!
Assessment method [6]
0
0
Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction = 50% compared to baseline, the higher number of patients the better
Query!
Timepoint [6]
0
0
6 week of treatments
Query!
Secondary outcome [7]
0
0
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced = 50%, Patients With One Previous Treatment Failure
Query!
Assessment method [7]
0
0
Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction = 50% compared to baseline, the higher number of patients the better
Query!
Timepoint [7]
0
0
6 weeks of treatment
Query!
Secondary outcome [8]
0
0
Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced = 50%, Patients With Two Previous Treatment Failure
Query!
Assessment method [8]
0
0
Response rate at end of study measured as number of patients with Montgomery Asberg Depression Rating Scale (MADRS) with total score reduction = 50% compared to baseline, the higher number of patients the better
Query!
Timepoint [8]
0
0
6 weeks of treatment
Query!
Secondary outcome [9]
0
0
Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients
Query!
Assessment method [9]
0
0
Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where lower value shows a larger improvement.
Query!
Timepoint [9]
0
0
6 weeks of treatment
Query!
Secondary outcome [10]
0
0
Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure
Query!
Assessment method [10]
0
0
Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.
Query!
Timepoint [10]
0
0
6 weeks of treatment
Query!
Secondary outcome [11]
0
0
Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure
Query!
Assessment method [11]
0
0
Change in global improvement measured by Clinical Global Impression Improvement (CGI-I). Scale from 1-4, where a lower value shows a larger improvement.
Query!
Timepoint [11]
0
0
6 weeks of treatment
Query!
Secondary outcome [12]
0
0
Change in Clinical Global Impression Scale (CGI-S), All Patients
Query!
Assessment method [12]
0
0
Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale form 1-7, where a lower value shows a larger improvement.
Query!
Timepoint [12]
0
0
6 weeks of treatment
Query!
Secondary outcome [13]
0
0
Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure
Query!
Assessment method [13]
0
0
Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.
Query!
Timepoint [13]
0
0
6 weeks of treatment
Query!
Secondary outcome [14]
0
0
Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure
Query!
Assessment method [14]
0
0
Change in severity of illness measured by Clinical Global Impression Scale (CGI-S). Scale from 1-7, where a lower value shows a larger improvement.
Query!
Timepoint [14]
0
0
6 weeks of treatment
Query!
Secondary outcome [15]
0
0
Change in Beck Depression Inventory (BDI)
Query!
Assessment method [15]
0
0
Self-rating assessment of depressive symptoms using Beck Depression Inventory (BDI). Scale from 0-63, where a lower value shows a larger improvement.
Query!
Timepoint [15]
0
0
6 weeks of treatment
Query!
Secondary outcome [16]
0
0
Change in Pain, Measured by Visual Analog Scale (VAS)
Query!
Assessment method [16]
0
0
Self-rating assessment of pain using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.
Query!
Timepoint [16]
0
0
6 weeks of treatment
Query!
Secondary outcome [17]
0
0
Change in Anxiety Measured by Visual Analog Scale (VAS)
Query!
Assessment method [17]
0
0
Self-rating assessment of anxiety using a visual analogue scale (VAS). Scale from 0-100, where a lower value shows a larger improvement.
Query!
Timepoint [17]
0
0
6 weeks of treatment
Query!
Secondary outcome [18]
0
0
Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory
Query!
Assessment method [18]
0
0
Self-rating assessment of anxiety measured by STAI, state anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)
Query!
Timepoint [18]
0
0
6 weeks of treatment
Query!
Secondary outcome [19]
0
0
Change in Anxiety Measured by STAI, Trait Anxiety Inventory
Query!
Assessment method [19]
0
0
Self-rating assessment of anxiety measured by State-Trait Anxiety Inventory (STAI), trait anxiety inventory (Scale 20-80, where a lower value shows a larger improvement)
Query!
Timepoint [19]
0
0
6 weeks of treatment
Query!
Secondary outcome [20]
0
0
Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4
Query!
Assessment method [20]
0
0
Sleeping quality measured by Montgomery-Asberg Depression Rating Scale (MADRS) item 4 (reduced sleep) (Scale 0-6, where a lower value shows a larger improvement)
Query!
Timepoint [20]
0
0
6 weeks of treatment
Query!
Secondary outcome [21]
0
0
Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)
Query!
Assessment method [21]
0
0
Self-rated sleeping quality measured by PSQI (Scale 0-21, subscales 0-3, 18 questions, where a lower value shows a larger improvement)
Query!
Timepoint [21]
0
0
6 weeks of treatment
Query!
Secondary outcome [22]
0
0
Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component
Query!
Assessment method [22]
0
0
Self rating assessment of quality in life using SF-36, mental component (Scale 0-100, where a higher value shows a larger improvement)
Query!
Timepoint [22]
0
0
6 weeks of treatment
Query!
Secondary outcome [23]
0
0
Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component
Query!
Assessment method [23]
0
0
Self rating assessment of quality in life using SF-36, physical component (Scale 0-100, where a higher value shows a larger improvement)
Query!
Timepoint [23]
0
0
6 weeks of treatment
Query!
Secondary outcome [24]
0
0
Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility
Query!
Assessment method [24]
0
0
Self rating assessment of quality in life using EQ-5D utility (Scale 0-100, where a higher value shows a larger improvement)
Query!
Timepoint [24]
0
0
6 weeks of treatment
Query!
Secondary outcome [25]
0
0
Change in Work Productivity and Activity Impairment: General Health (WPAI:GH)
Query!
Assessment method [25]
0
0
Self rating assessment of working productivity using WPAI:GH (Scale 0 to number of hours worked during a week multiplied with the salary in Euro, a lower value shows a larger improvement)
Query!
Timepoint [25]
0
0
6 weeks of treatment
Query!
Secondary outcome [26]
0
0
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients
Query!
Assessment method [26]
0
0
The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm (225, 229 or 221).
Query!
Timepoint [26]
0
0
6 weeks of treatment
Query!
Secondary outcome [27]
0
0
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure
Query!
Assessment method [27]
0
0
The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.
Query!
Timepoint [27]
0
0
6 weeks of treatment
Query!
Secondary outcome [28]
0
0
Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures
Query!
Assessment method [28]
0
0
The physician has evaluated the therapeutic effect and the side effect combined at end of study. Patients with a 'marked/moderate' therapeutic effect and 'None/Do Not Significantly Interfere' side effect has been added. The higher values show more patients with a treatment effect without any side-effect. The range is from 0 patients to the maximum number of patients in the treatment arm.
Query!
Timepoint [28]
0
0
6 week of treatments
Query!
Eligibility
Key inclusion criteria
* Documented clinical diagnosis as confirmed by the M.I.N.I. meeting criteria from the Diagnostic and Statistical Manual of Mental disorders, 4th Edition (DSM-IV) for any of the following:296.2x MDD, Single Episode296.3x MDD, Recurrent Episode
* Current episode of depression present, at least 42 days prior to enrolment but not more than 18 months
* MADRS-Score = 25 at enrolment and randomisation
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Patients with a DSM-IV Axis I disorder other than MDD within 6 months of randomisation
* Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status
* Patients who, in the investigator's judgment pose a current serious suicidal or homicidal risk, or have made a suicide attempt within the past 6 months
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
688
Query!
Recruitment in Australia
Recruitment state(s)
ACT,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Research Site - Garran
Query!
Recruitment hospital [2]
0
0
Research Site - Brisbane
Query!
Recruitment hospital [3]
0
0
Research Site - Everton Park
Query!
Recruitment hospital [4]
0
0
Research Site - Townsville
Query!
Recruitment hospital [5]
0
0
Research Site - Gilberton
Query!
Recruitment hospital [6]
0
0
Research Site - Clayton
Query!
Recruitment hospital [7]
0
0
Research Site - Frankston
Query!
Recruitment hospital [8]
0
0
Research Site - Heidelberg
Query!
Recruitment hospital [9]
0
0
Research Site - Malvern
Query!
Recruitment hospital [10]
0
0
Research Site - Prahran
Query!
Recruitment hospital [11]
0
0
Research Site - Richmond
Query!
Recruitment postcode(s) [1]
0
0
- Garran
Query!
Recruitment postcode(s) [2]
0
0
- Brisbane
Query!
Recruitment postcode(s) [3]
0
0
- Everton Park
Query!
Recruitment postcode(s) [4]
0
0
- Townsville
Query!
Recruitment postcode(s) [5]
0
0
- Gilberton
Query!
Recruitment postcode(s) [6]
0
0
- Clayton
Query!
Recruitment postcode(s) [7]
0
0
- Frankston
Query!
Recruitment postcode(s) [8]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [9]
0
0
- Malvern
Query!
Recruitment postcode(s) [10]
0
0
- Prahran
Query!
Recruitment postcode(s) [11]
0
0
- Richmond
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Graz
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Klagenfurt
Query!
Country [3]
0
0
Austria
Query!
State/province [3]
0
0
Salzburg
Query!
Country [4]
0
0
Austria
Query!
State/province [4]
0
0
Wels
Query!
Country [5]
0
0
Austria
Query!
State/province [5]
0
0
Wiener NEUSTADT
Query!
Country [6]
0
0
Austria
Query!
State/province [6]
0
0
Wien
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Assebroek
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Diest
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Liege
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Tielt
Query!
Country [11]
0
0
Bulgaria
Query!
State/province [11]
0
0
Veliko Tarnovo
Query!
Country [12]
0
0
Bulgaria
Query!
State/province [12]
0
0
Kardjali
Query!
Country [13]
0
0
Bulgaria
Query!
State/province [13]
0
0
Pazardjik
Query!
Country [14]
0
0
Bulgaria
Query!
State/province [14]
0
0
Pleven
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Ruse
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Sofia
Query!
Country [17]
0
0
Bulgaria
Query!
State/province [17]
0
0
Varna
Query!
Country [18]
0
0
Denmark
Query!
State/province [18]
0
0
Esbjerg N
Query!
Country [19]
0
0
Denmark
Query!
State/province [19]
0
0
Frederiksberg
Query!
Country [20]
0
0
Denmark
Query!
State/province [20]
0
0
Odense
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Aachen
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Achim
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Augsburg
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Bad Homburg
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Bad Honnef
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Bad Saarow
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Berlin
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Bielefeld
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Bochum
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Butzbach
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Chemnitz
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Dresden
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Duren
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Dusseldorf
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Ellwangen
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Erbach
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Gelsenkirchen
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Gutersloh
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Halle
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Hattingen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Herborn
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Kassel
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Kothen
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Neu-isenburg
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Neubrandenburg
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Nurnberg
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Oldenburg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Ostfildern
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Schwerin
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Stuttgart
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Westerstede
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Wurzburg
Query!
Country [53]
0
0
Hungary
Query!
State/province [53]
0
0
Budapest
Query!
Country [54]
0
0
Hungary
Query!
State/province [54]
0
0
Gyor
Query!
Country [55]
0
0
Hungary
Query!
State/province [55]
0
0
Gyula
Query!
Country [56]
0
0
Hungary
Query!
State/province [56]
0
0
Nyiregyhaza
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
BZ
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
CA
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
PI
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
RM
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Bolzano
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Catania
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Napoli
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Roma
Query!
Country [65]
0
0
Portugal
Query!
State/province [65]
0
0
Braga
Query!
Country [66]
0
0
Portugal
Query!
State/province [66]
0
0
Coimbra
Query!
Country [67]
0
0
Portugal
Query!
State/province [67]
0
0
Lisboa
Query!
Country [68]
0
0
Portugal
Query!
State/province [68]
0
0
Santarem
Query!
Country [69]
0
0
Romania
Query!
State/province [69]
0
0
Bucharest
Query!
Country [70]
0
0
Romania
Query!
State/province [70]
0
0
Craiova
Query!
Country [71]
0
0
Romania
Query!
State/province [71]
0
0
Galati
Query!
Country [72]
0
0
Romania
Query!
State/province [72]
0
0
Sibiu
Query!
Country [73]
0
0
Slovakia
Query!
State/province [73]
0
0
Bratislava
Query!
Country [74]
0
0
Slovakia
Query!
State/province [74]
0
0
Krupina
Query!
Country [75]
0
0
Slovakia
Query!
State/province [75]
0
0
Levice
Query!
Country [76]
0
0
Slovakia
Query!
State/province [76]
0
0
Liptovsky Mikulas
Query!
Country [77]
0
0
Slovakia
Query!
State/province [77]
0
0
Michalovce Stranany
Query!
Country [78]
0
0
Slovakia
Query!
State/province [78]
0
0
Presov
Query!
Country [79]
0
0
Slovakia
Query!
State/province [79]
0
0
Roznava
Query!
Country [80]
0
0
Slovakia
Query!
State/province [80]
0
0
Zilina-bytcica
Query!
Country [81]
0
0
Slovakia
Query!
State/province [81]
0
0
Zlate Moravce
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Asturias
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Castilla Leon
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Cataluna
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Galicia
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Surrey
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Warrington
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
West Sussex
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Coventry
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Glasgow
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Harrow
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Hull
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Winsford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an selective serotonin reuptake inhibitor or Venlafaxine versus Quetiapine extended release monotherapy in subjects with treatment resistant depression as assessed by the changes from randomisation to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. As an independent objective, the primary objective will also be evaluated in two subgroups of patients: (1) patients who were resistant to two previous antidepressant therapies and (2) in the subgroup of patients with one previous failure.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00789854
Query!
Trial related presentations / publications
Bauer M, Dell'osso L, Kasper S, Pitchot W, Dencker Vansvik E, Kohler J, Jorgensen L, Montgomery SA. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord. 2013 Oct;151(1):209-19. doi: 10.1016/j.jad.2013.05.079. Epub 2013 Jun 27.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Michael Bauer, professor
Query!
Address
0
0
Germany
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00789854
Download to PDF